Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study
Authors:
- M. BerkMBM. Berk
- C. IchimCIC. Ichim
- S. BrookSBS. Brook
- 1 March 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 16 (2) , 87-92
Abstract
The negative symptoms of schizophrenia remain a major clinical challenge. Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects. Many of these pharmacological actions have clinical or preclinical evidence of efficacy in schizophrenia. This study was a 6-week randomized placebo-controlled trial of mirtzepine or placebo add on to haloperidol 5 mg in the treatment of 30 patients with DSM-IV schizophrenia. The primary finding of the trial was a 42% reduction in Positive and Negative Syndrome Scale (PANSS) negative symptom scores in the mirtazapine group compared to placebo at the end of 6 weeks (mirtazapine 13.9, SD 1.56; placebo 23.9, SD 1.56; P = 0.000, F = 20.31, d.f. = 1). The PANNS total scores, Clinical Global Impression severity and improvement scales in addition showed superiority of mirtazapine over placebo. There was no difference between the groups on the Hamilton depression scale at endpoint, suggesting that the improvement in negative symptoms was not an artifact of mood improvement. These results suggest a potential role for mirtazapine in the negative symptoms of schizophrenia.Keywords
This publication has 21 references indexed in Scilit:
- Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjectsPsychoneuroendocrinology, 1999
- Enhanced Cortical Dopamine Output and Antipsychotic-like Effects of Raclopride by α 2 Adrenoceptor BlockadeScience, 1999
- Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot studyInternational Clinical Psychopharmacology, 1999
- Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment ResponseHarvard Review of Psychiatry, 1998
- Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats.Psychopharmacology, 1998
- Fluoxetine augmentation of clozapine treatment in patients with schizophreniaAmerican Journal of Psychiatry, 1996
- Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of SchizophreniaCNS Drugs, 1996
- The Psychopharmacology of 5‐HT3Receptors*Basic & Clinical Pharmacology & Toxicology, 1992
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- A Double-Blind Trial of Amitriptyline/Perphenazine, Perphenazine and Placebo in Chronic Withdrawn Inert SchizophrenicsThe British Journal of Psychiatry, 1967